Compare Biogen Inc (BIIB) vs Freeport-McMoRan Inc (FCX) Price & Performance

Biogen (BIIB) trades at $210.65, up 3.32% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 37.1 and net income margin of 8.32%, supported by positive cash flow trends. Recent news highlights the acquisition of RayThera Inc. and raised 2026 guidance, reflecting strategic growth initiatives.

Outlook is positive with analyst consensus price target of $234.47, though risks include competitive pressures and earnings volatility. Investment opportunity lies in pipeline expansion and Alzheimer's drug traction, balanced by margin compression concerns from legacy MS portfolio declines.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.